takisbiotech

Internal
Research

Driving Innovation with Scientific Research

Discover Takis’ commitment to advancing scientific research as the cornerstone of innovation. A showcase of the company’s cutting-edge technologies, groundbreaking discoveries, and contributions to the fields of genetic engineering, immunology, and biotechnology. Learn about Takis’ dedication to transforming scientific knowledge into impactful solutions, driving progress in healthcare and beyond.

Program Platform Target Indication
TK001 mAbs ErbB3 receptor Solid Tumor
TK001 is a humanized IgG1 monoclonal antibody that targets the ErbB3 receptor tyrosine kinase. This receptor is a crucial step in cancer development and, more importantly, in the mechanisms of resistance to oncological therapies. TK001 can block ErbB3 receptor activation by competing with the ligand NRG for ErbB3 binding, leading to a dose-dependent inhibition of ErbB3, Akt and MAPK phosphorylation. Colony formation assays revealed significant inhibition of tumor cell survival in vitro. In vivo, it significantly delayed tumor growth in a pancreatic cancer xenograft model and demonstrated efficacy in various preclinical predictive models for humans. Toxicology study showed good tolerability, with minimal inflammatory responses observed at higher doses.
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Program Platform Target Indication
TK002 BsTCE ErbB3xCD3 Solid Tumor
TK002 is an HER3xCD3 bispecific T cell engager antibody for the treatment of solid tumors dependent on the expression of the ErbB3 receptor. This receptor is a crucial step in the development of cancer and, more importantly, in the mechanisms of resistance to oncological therapies. Unlike conventional antibodies, BsTCEs have the unique ability to redirect T lymphocytes towards specific antigens expressed by tumor cells, directly activating them for an effective antitumor action. The antibody was developed according to the knob into hole approach and is able to bind both the HER3 receptor expressed on tumor cells and the CD3 receptor on T cells, activating T cells and directing the attack against HER3-positive tumor cells. This dual specificity showed an effective activation of CD4 and CD8 T lymphocytes, as well as the expression of activation markers and cytotoxic mediators, as demonstrated by co-culture and in vivo experiments.
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ProgramPlatformTargetIndication
TK003DNA vaccineTelomeraseTERT-positive Tumor

TK003 is a DNA plasmid vaccine targeting telomerase reverse transcriptase (TERT), the enzyme responsible for telomere lengthening during DNA replication. Normally inactive in adult somatic cells, telomerase becomes reactivated in over 85% of malignant tumors, making it a promising target for cancer immunotherapy. TK003 is designed to generate an immune response specifically against TERT-expressing tumors, with potential as a universal cancer vaccine. Preclinical studies in various animal models, from mice to dogs, have demonstrated Tel-eVax’s strong biosafety profile and its efficacy against TERT-positive tumors.

DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ProgramPlatformTargetIndication
TK004DNA vaccineSARS-CoV-2 RBDCovid 19

TK004 is a first-generation DNA plasmid vaccine encoding a secreted monomeric form of the SARS-CoV-2 spike protein RBD, delivered via intramuscular electroporation. Designed to trigger a robust immune response, it induces high levels of anti-SARS-CoV-2 neutralizing antibodies and a potent Th-1 cell-mediated reaction, with strong tolerability. The DNA platform allows for cost-effective production and rapid adaptation to target viral mutations and regional variants. Notably, DNA’s stability at room temperature facilitates transport without a cold chain, a significant logistical advantage. COVID-eVax completed a successful Phase I clinical trial in Italy during the pandemic, in partnership with Rottapharm Biotech and IGEA.

DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3

CONTACT US

We'd like to hear from you!

Get in touch